Curex Real Customer Outcomes: An Independent Clinical Synthesis

What Curex Prescribes and How the Model Works

Curex operates as an asynchronous-to-synchronous telehealth practice: patients complete an online intake, a clinician reviews labs and history, and a prescription is issued within 24 to 72 hours. The platform focuses on GLP-1 receptor agonists for weight management, dispatching compounded semaglutide or compounded tirzepatide from partner 503A or 503B-licensed pharmacies.

The cash-pay model removes insurance gatekeeping, which can accelerate access for patients who meet clinical criteria. The FDA's guidance on compounded GLP-1 drugs, updated in 2024, confirms that 503A and 503B pharmacies may continue compounding semaglutide while the active shortage listing stands, but notes that compounded copies of tirzepatide carry heightened scrutiny because the FDA removed tirzepatide from the shortage list in December 2024 [1].

How the Intake Process Works

Patients submit a standard metabolic history form covering weight, comorbidities, contraindications (personal or family history of medullary thyroid carcinoma, MEN-2), and any prior GLP-1 exposure. A licensed clinician then reviews the submission.

Labs are not always required upfront, which differs from in-person obesity-medicine practice where baseline HbA1c, lipid panel, and thyroid function are standard before initiation. The American Diabetes Association (ADA) 2024 Standards of Care state that "assessment of glycemic status, blood pressure, and weight should occur at every clinical encounter for patients on GLP-1 receptor agonists" [2].

Compounded vs. Brand-Name GLP-1s

Curex uses compounded formulations rather than branded Ozempic, Wegovy, or Mounjaro. Compounded semaglutide contains the same active molecule, but the FDA has not reviewed the specific compounded product for safety, efficacy, or manufacturing consistency. A 2023 FDA safety communication flagged reports of dosing errors and adverse events tied to compounded semaglutide injections, including hospitalizations [3].

This does not mean compounded products are inherently unsafe, but patients should confirm the dispensing pharmacy holds a current 503A or 503B license and that certificates of analysis (CoA) are available on request.

What the Clinical Trials Actually Show About GLP-1 Outcomes

No Curex-specific randomized controlled trial exists. Any honest assessment of likely outcomes must therefore use the published phase-3 data for semaglutide and tirzepatide as the ceiling of what is pharmacologically achievable under ideal conditions.

Semaglutide: STEP-1 and STEP-4

STEP-1 (N=1,961) randomized adults with obesity (BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity) to subcutaneous semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight loss was 14.9% on semaglutide versus 2.4% on placebo (P<0.001) [4]. More than 86% of semaglutide participants achieved at least 5% weight loss.

STEP-4 (N=803) is critical for interpreting telehealth outcomes. Participants who achieved stabilization on semaglutide were then randomized to continue or switch to placebo. Those who switched regained two-thirds of their lost weight within 48 weeks [5]. This means a telehealth platform must support continuous prescribing and monitoring, not just initiation.

Tirzepatide: SURMOUNT-1

SURMOUNT-1 (N=2,539) tested tirzepatide 5 mg, 10 mg, and 15 mg weekly versus placebo at 72 weeks in adults with obesity or overweight plus comorbidities. At the 15 mg dose, mean weight reduction was 20.9% (P<0.001) [6]. Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the leading reason for discontinuation, affecting roughly 4 to 6 percent of participants depending on dose.

Cardiovascular Evidence

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease, over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [7]. This is the strongest outcome-level evidence for the drug class outside of purely metabolic endpoints.

Realistic Curex Patient Outcomes vs. Trial Benchmarks

Trial benchmarks reflect supervised clinical settings with protocolized dose escalation, regular in-person visits, and nutritional counseling. Real-world telehealth outcomes typically run 20 to 40 percent below trial results due to adherence gaps, dose capping by pharmacy supply, and loss to follow-up.

A 2023 analysis of real-world semaglutide use in a large integrated health system (N=3,476) found mean 6-month weight loss of 5.9%, compared to 10.7% in STEP-1 at the same timepoint [8]. The gap was largely explained by dose escalation failures: 41% of real-world patients never reached the 2.4 mg maintenance dose.

The HealthRX clinical team uses a three-tier outcome framework to contextualize GLP-1 telehealth results:

• Tier 1 (optimal): Full dose escalation to maintenance, regular check-ins every 4 to 8 weeks, lifestyle counseling integrated. Expected outcome: 12 to 18% weight loss at 52 weeks.
• Tier 2 (typical telehealth): Partial dose escalation, asynchronous follow-up, no structured counseling. Expected outcome: 6 to 10% weight loss at 52 weeks.
• Tier 3 (suboptimal): Dose stalled by side effects or supply gaps, irregular follow-up, no behavioral support. Expected outcome: <5% weight loss, high discontinuation.

Where a given patient lands depends substantially on the prescribing platform's escalation protocol and how aggressively side effects are managed. Nausea at 0.5 mg semaglutide often resolves at the 4-week mark. Stopping entirely at that point rather than managing with dose hold or anti-emetic guidance forfeits the majority of potential benefit.

Is Curex Legit? Regulatory and Quality Markers to Verify

"Legit" for a telehealth GLP-1 provider requires checking four distinct dimensions.

Prescriber Licensure

Every prescribing clinician should hold a valid state license in the patient's state. The National Practitioner Data Bank (NPDB) allows consumers to request a limited query, and state medical boards publish disciplinary records. Platforms that route all prescriptions through a single out-of-state clinician without a valid multi-state compact license are operating in a gray zone.

Pharmacy Credentials

Compounding pharmacies should hold a current 503A (traditional compounding) or 503B (outsourcing facility) registration. The FDA publishes a searchable list of registered 503B outsourcing facilities [9]. A 503B facility is subject to FDA inspection under Current Good Manufacturing Practice (CGMP) standards, providing a higher quality bar than 503A. Patients using any telehealth GLP-1 platform should ask which specific pharmacy fills their prescription and verify its registration.

Prescribing Criteria

Responsible GLP-1 prescribing follows the FDA-approved indications: BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) [10]. Platforms that prescribe to patients below these thresholds, or skip contraindication screening for thyroid cancer history or pancreatitis, carry meaningful clinical liability.

Follow-Up Cadence

The Obesity Medicine Association (OMA) recommends follow-up at 4 weeks after initiation, then every 4 to 8 weeks during dose escalation, with assessment of weight, tolerability, and metabolic markers at each encounter [11]. A platform offering only an annual check-in after the initial prescription does not meet this standard.

Curex Cost Breakdown and Value Assessment

Curex charges cash-pay patients directly. No insurance is accepted. The approximate cost structure as of early 2025 is as follows.

Monthly membership and consultation fees typically run $50 to $99. Compounded semaglutide injections add $199 to $349 per month depending on dose tier. Compounded tirzepatide runs higher, typically $299 to $499 per month. Combined annual cost therefore ranges from roughly $2,988 to $7,176 for tirzepatide at the high end.

For comparison, branded Wegovy (semaglutide 2.4 mg) has a list price of approximately $1,349 per month without insurance, though manufacturer savings programs (Novo Nordisk's Wegovy WeightLoss Card) can reduce out-of-pocket cost to $0 to $225 per month for eligible commercially insured patients [12]. The lower cash cost of compounded alternatives is the primary competitive advantage, but that advantage narrows for patients who qualify for manufacturer programs.

A 2022 cost-effectiveness analysis published in JAMA Network Open found that semaglutide for weight loss was cost-effective at a threshold of $150,000 per quality-adjusted life year (QALY) gained when the annual drug cost was at or below $7,600, assuming a 15% body-weight reduction [13]. Compounded pricing keeps most patients well below that threshold, provided outcomes approach trial benchmarks.

Curex vs. Alternatives: A Comparison of GLP-1 Telehealth Platforms

The GLP-1 telehealth space includes Hims and Hers, Ro Body, Found, WeightWatchers Clinic (formerly Sequence), and Henry Meds, among others. Meaningful differentiation sits across four axes.

Drug Formulary

Most platforms offer compounded semaglutide. Fewer offer compounded tirzepatide, especially after the FDA's December 2024 tirzepatide shortage-list removal. Platforms that continue prescribing compounded tirzepatide post-removal are operating under heightened regulatory risk.

Behavioral Support

Found and WeightWatchers Clinic integrate structured behavioral coaching. Ro Body includes a 12-week curriculum. Curex's behavioral support offering is less structured by comparison. This matters because a meta-analysis of 39 trials (N=10,965) found that GLP-1 agonists combined with intensive behavioral intervention produced 4.1% greater weight loss than drug alone (P<0.001) [14].

Lab Requirements

Some platforms (Henry Meds, Found) require or strongly encourage baseline metabolic labs. Others complete prescribing from self-reported history. Baseline labs are not merely administrative. A fasting glucose above 126 mg/dL at intake shifts the clinical picture from obesity management to type 2 diabetes management, which carries different drug selection considerations and monitoring requirements per ADA 2024 guidelines [2].

Prescriber Access

Platforms differ in whether patients can reach their prescriber synchronously (video visit) or only asynchronously (messaging). The American Telemedicine Association recommends that synchronous visits be available for initial prescribing of Schedule IV and higher-risk drugs [15]. GLP-1 agents are not scheduled, but the principle of synchronous capability for complex initiation decisions applies.

Side Effect Management: What Separates Good Platforms from Poor Ones

GLP-1 receptor agonist side effects are well-characterized. Nausea affects roughly 44% of patients on semaglutide 2.4 mg in the first 20 weeks and resolves in most by week 28 [4]. Vomiting occurs in 24%, diarrhea in 30%, constipation in 24%.

Platforms that lack a protocol for managing these side effects will see high early discontinuation. The standard clinical approach involves:

1. Holding dose escalation when nausea is present rather than advancing on schedule.
2. Using ondansetron 4 mg as needed for acute nausea in patients without QTc prolongation.
3. Advising smaller meals, reduced fat intake, and avoiding eating within 2 hours of injection.
4. Distinguishing nausea from the rarer but serious signal of acute pancreatitis, which requires immediate escalation [16].

Acute pancreatitis risk with GLP-1 agonists remains contested in the literature. A 2014 meta-analysis in JAMA Internal Medicine (N=55,451 patient-years) found no statistically significant increase in pancreatitis with GLP-1 agonists versus comparators (OR 1.11; 95% CI 0.57 to 2.17) [17]. Still, the FDA label for semaglutide carries a warning to discontinue if pancreatitis is suspected, and no telehealth platform should ignore persistent severe abdominal pain in a patient on these agents.

Who Is a Good Candidate for Curex Specifically?

The ideal Curex patient is someone who meets standard BMI criteria, has no contraindications, prefers a lower-cost compounded option over branded GLP-1s, is comfortable with injectable medications, and has sufficient self-directed adherence to maintain regular follow-up.

Curex is likely a poor fit for patients who need intensive behavioral support, who have complex metabolic comorbidities requiring specialist co-management, who prefer synchronous prescriber relationships, or who have had prior adverse reactions to GLP-1 therapy that require careful re-challenge protocols.

Patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should not use GLP-1 receptor agonists regardless of platform. The FDA label for semaglutide states this contraindication explicitly [10]. No intake process should clear a patient with this history.

Monitoring Standards Every GLP-1 Patient Should Expect

Regardless of which platform a patient uses, minimum monitoring during GLP-1 therapy should include weight at every contact, blood pressure and pulse at every contact, symptom review for GI adverse events, and HbA1c measurement at initiation and every 3 months if the patient has prediabetes or diabetes. The ADA 2024 Standards of Care recommend reassessing cardiovascular risk annually for patients on chronic weight-management pharmacotherapy [2].

Heart rate increases of 1 to 4 beats per minute are commonly seen with semaglutide. Clinically significant tachycardia (persistent resting heart rate above 100 BPM) warrants dose review. A 2021 review in Circulation noted that GLP-1-associated heart rate elevation does not appear to increase arrhythmia risk in the short term, but long-term data beyond 5 years remain limited [18].

Bone density monitoring is relevant for patients losing more than 10% body weight over 12 months. Rapid weight loss is associated with bone mineral density reduction, and a 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=407) found that semaglutide users losing greater than 15% body weight had a statistically significant reduction in hip bone mineral density at 68 weeks [19].